Published in New England Journal of Medicine · View the paper (DOI)
A clinical trial demonstrates the impact of nusinersen on older patients with spinal muscular atrophy (SMA), showing significant improvements in motor function scores. The study, known as CHERISH, enrolled 126 children aged 2-12 and found that 57% experienced an increase of at least three points in functioning scores.
Coverage from 2 institutions